Medline (MDLN) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.50
- Estimate
- $0.32
- Surprise
- +55.8%
- Revenue (period 2026-06-27)
- $7.68B
- Score today
- 5.4/10
Revenue source: mixed.
How the report landed
Medline (MDLN) beat the $0.32 estimate with adjusted EPS of $0.50 — a large 55.8% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates MDLN Sell at 5.4/10; no pre/post engine snapshot brackets this report.
3 of the last 3 quarters beat the estimate; this quarter's +55.8% surprise compares with a +32.7% four-quarter average. Next scheduled report: 2026-11-04.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (3/4)
What argues against it
- Concentration risk — Customer: Vizient Supply, HealthTrust Purchasing Group, and Premier Healthcare Alliance (GPOs) (69.0%)
- V7 low-quality RISK_OFF penalty: -0.5 (Q=4.2)
- Earnings in 6 days (event risk)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $32.46
- Price target
- $39.88
- Stop
- $31.10
- Upside to target
- +22.9%
- Reward-to-risk
- 3.6:1
The stock trades at 80.9× trailing but 20.6× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 20 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.
MDLN at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Instruments & Supplies
- Market cap
- $43.55B
- P/E (fwd)
- 20.6
- P/E (ttm)
- 80.9
- 52-week range
- $31.49–$50.88
- Off 52-week high
- 36.2%
- RSI (14)
- 20
- Volume vs avg
- 0.01×
- Score today
- 5.4/10